HIGHLIGHTS
- who: HDAC and collaborators from the State Key Laboratory of Quality Research in Chinese Medicine and School of Pharmacy, Macau University of Science and Technology, Macau, China have published the Article: HDAC4 Inhibitors as Antivascular Senescence Therapeutics, in the Journal: Oxidative Medicine and Cellular Longevity of 29/06/2022
- what: In this research histone deacetylation 4 (HDAC4) was studied a potential therapeutic target in vascular is a specific class II histone deacetylation protein that participates in epigenetic modifications and deacetylation of heat shock proteins and various transcription factors. The authors report on the role of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.